August 8, 2024By Raj Caribou Biosciences, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, recently announced its financial results for the second quarter of 2024. The company also provided significant updates on its clinical programs, highlighting its commitment to advancing innovative therapies for hematologic malignancies and autoimmune diseases. Financial Snapshot As of June 30, 2024, Caribou … Continue reading Caribou Biosciences Q2 2024 Earnings: Strong Clinical Progress and Extended Cash Runway